Introduction: The GHRH/GHRP Research Combination

CJC-1295 and Ipamorelin are two of the most extensively studied growth hormone secretagogues (GHS) in peptide research. They are frequently examined together because they act on complementary pathways to stimulate growth hormone (GH) release from the pituitary gland — CJC-1295 as a GHRH analogue, and Ipamorelin as a selective GHRP (growth hormone-releasing peptide).

Note: All content on this page is for research and educational purposes only. These compounds are intended for in vitro and laboratory research use and are not approved for human or veterinary administration.

Understanding the Two Compounds

CJC-1295

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH). It works by binding to GHRH receptors on the pituitary, stimulating the release of GH. The DAC (Drug Affinity Complex) version of CJC-1295 binds to albumin in plasma, significantly extending its half-life to approximately 6–8 days in animal models. The non-DAC version (also known as Mod GRF 1-29) has a shorter active window and is typically studied in protocols requiring more frequent administration.

Ipamorelin

Ipamorelin is a pentapeptide GHRP that selectively activates ghrelin receptors (GHS-R1a) on both the pituitary and hypothalamus. Its key characteristic in research is its selectivity — unlike earlier GHRPs such as GHRP-2 and GHRP-6, Ipamorelin demonstrates minimal stimulation of cortisol, prolactin, or ACTH at research doses, making it a cleaner model for isolating GH-specific effects.

Why Researchers Combine Them

The rationale for the CJC-1295/Ipamorelin combination lies in dual-pathway stimulation:

• CJC-1295 amplifies the baseline GH pulse via GHRH receptor agonism
• Ipamorelin triggers a separate, additive GH release via ghrelin receptor agonism
• Together, they produce a synergistic GH pulse that is greater than either compound alone, based on preclinical data
• Ipamorelin’s selectivity profile helps researchers attribute observed effects specifically to GH axis stimulation

Key Research Areas

Body Composition

GH secretagogue research frequently examines effects on lean mass and fat mass in animal models. Elevated GH pulses are associated with enhanced lipolysis and protein synthesis pathways, areas relevant to metabolic and body composition research.

Recovery and Tissue Repair

GH plays a role in collagen synthesis, wound healing, and connective tissue repair. Research protocols using CJC-1295/Ipamorelin have explored these pathways, particularly in models of tissue damage and post-exertional recovery.

Sleep Architecture

GH is predominantly secreted during slow-wave sleep. Some research has examined whether GH secretagogues administered prior to sleep onset may interact with natural GH pulsatility, making sleep quality a secondary variable in certain protocols.

Bone Density

IGF-1, downstream of GH stimulation, is associated with bone mineral density. Studies on GHRPs and GHRH analogues have included skeletal markers as endpoints in ageing and metabolic research contexts.

Storage and Handling (Research Use)

• Lyophilised powder: Store at −20°C, protected from light and moisture. Shelf-stable for 12–24 months under proper conditions.
• Reconstitution: Use sterile bacteriostatic water. Add slowly to the vial, swirl gently. Do not shake or vortex.
• Reconstituted solution: Refrigerate at 2–8°C. Use within 30 days. Avoid repeated freeze-thaw cycles.
• Handling: Use sterile technique throughout. Inspect for particulates or cloudiness before use.

Comparison with Other GH-Axis Peptides

Researchers focusing on growth hormone secretagogues may also be interested in other recovery-oriented peptides. The Recovery and Sports collection at Meytrix Therapeutics covers a range of compounds studied in exercise physiology and tissue recovery contexts.

For researchers exploring the intersection of metabolic and anabolic pathways, the broader full catalogue provides additional compound options across multiple research domains.

Research Considerations

Most CJC-1295/Ipamorelin data is derived from animal studies and early-phase clinical trials. Researchers should:

• Review current literature including GH pulsatility studies and receptor binding data
• Design protocols with appropriate controls to isolate GH-specific effects
• Ensure sourcing from suppliers with verified purity certificates (HPLC, mass spectrometry)
• Comply with all applicable institutional ethics and regulatory frameworks

Summary

The CJC-1295/Ipamorelin combination represents one of the most studied dual-pathway approaches in growth hormone secretagogue research. Its synergistic mechanism, combined with Ipamorelin’s favourable selectivity profile, makes it a well-characterised model for GH axis research across recovery, body composition, and longevity-adjacent study areas.

Explore the CJC-1295/Ipamorelin compound and the Titan Stack bundle available through Meytrix Therapeutics for your research requirements.